UroGen Pharma Ltd. (URGN)

USD 10.79

(-4.77%)

Market Cap (In USD)

455.33 Million

Revenue (In USD)

82.71 Million

Net Income (In USD)

-102.24 Million

Avg. Volume

506.48 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.6-20.7
PE
-
EPS
-
Beta Value
1.126
ISIN
IL0011407140
CUSIP
M96088105
CIK
1668243
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Elizabeth A. Barrett
Employee Count
-
Website
https://www.urogen.com
Ipo Date
2017-05-04
Details
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.